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Abstract
Chronic administration of capsiate is known to accelerate whole-body basal energymetabolism,
but the consequences in exercising skeletal muscle remain very poorly documented. In order to
clarify this issue, the effect of 2-week daily administration of either vehicle (control) or purified
capsiate (at 10- or 100-mg/kg body weight) on skeletal muscle function and energetics were in-
vestigated throughout a multidisciplinary approach combining in vivo and in vitro measurements
in mice. Mechanical performance and energy metabolismwere assessed strictly non-invasively
in contracting gastrocnemiusmuscle using magnetic resonance (MR) imaging and 31-phos-
phorus MR spectroscopy (31P-MRS). Regardless of the dose, capsiate treatments markedly
disturbed basal bioenergetics in vivo including intracellular pH alkalosis and decreased phos-
phocreatine content. Besides, capsiate administration did affect neither mitochondrial uncoupl-
ing protein-3 gene expression nor both basal andmaximal oxygen consumption in isolated
saponin-permeabilized fibers, but decreased by about twofold theKm of mitochondrial respira-
tion for ADP. During a standardized in vivo fatiguing protocol (6-min of repeatedmaximal iso-
metric contractions electrically induced at a frequency of 1.7 Hz), both capsiate treatments
reduced oxidative cost of contraction by 30-40%, whereas force-generating capacity and fatiga-
bility were not changed.Moreover, the rate of phosphocreatine resynthesis during the post-elec-
trostimulation recovery period remained unaffected by capsiate. Both capsiate treatments
further promotedmuscle mass gain, and the higher dose also reduced body weight gain and
abdominal fat content. These findings demonstrate that, in addition to its anti-obesity effect,
capsiate supplementation improves oxidative metabolism in exercising muscle, which strength-
en this compound as a natural compound for improving health.
Introduction
Obesity has become one of the most important public health problems in developed as well as
in developing countries. It has been largely acknowledged as an increasing risk factor for insu-
lin resistance, type 2 diabetes, cardiovascular diseases, stroke and also some types of cancers
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[1]. The fundamental cause of obesity is an imbalance between energy intake and expenditure
leading to weight gain and excessive accumulation of adipose tissue. In that context, the use of
natural compounds stimulating energy expenditure, in complement of energy intake reduction,
represents an interesting approach for the treatment and prevention of obesity.
Capsiate is a nonpungent capsaicin-related compound extracted from the fruit of the CH-
19 sweet pepper wherein it is highly concentrated [2]. Chronic administration of capsiate has
been reported to promote fat loss in both humans [3] and rodents [4, 5] in the absence of any
adverse effect or toxicological changes [6, 7]. This anti-obesity effect would be mediated by an
acceleration of basal fatty-acid oxidation in mitochondria [3, 5, 8]. The exact mechanisms acti-
vated by capsiate are still unclear, despite the involvement of energy dissipation through un-
coupling processes in adipose tissue and skeletal muscle has been evoked [9]. Oral
administration of capsiate has been especially shown to activate transient potential vanilloid 1
(TRPV1) receptor, which in turn increases fat tissues lipolysis via sympathetic nervous system
and thermogenesis [10–12].
Mitochondrial oxidative phosphorylation represents an important source of energy in both
resting and exercising muscle [13]. Then, in addition to its anti-obesity effect, chronic adminis-
tration of capsiate could be beneficial for working muscle. Nevertheless, very few studies have
investigated so far the effects of chronic administration of capsiate on muscle function and en-
ergetics. Two-week daily administration of a high dose of capsiate (100 mg/kg body weight) in
rat has been shown to significantly reduce (-60%) basal expression of mitochondrial uncoupl-
ing protein-3 (UCP3) [4], a mitochondrial inner membrane protein that is highly and prefer-
entially expressed in skeletal muscle and that plays a major role in muscle energy expenditure
through the uncoupling of mitochondrial oxygen consumption by the respiratory chain from
ATP synthesis [14]. These changes were associated to the reduction of both intracellular acido-
sis and phosphocreatine (PCr) consumption in exercising gastrocnemius muscle whereas
force-generating capacity remained unchanged, thereby suggesting a lower glycolytic flux and
a compensatory higher contribution to ATP production [4]. On the other hand, administration
of a lower dose of capsiate (10 mg/kg) for the same duration (2-week) in mice has been related
to body fat reduction, acceleration of both oxygen consumption (an index of energy expendi-
ture) and fatty-acid oxidation, and improvement of swimming endurance [5, 15], but contrary
to what has been reported previously [4] did not affect UCP3 expression [9]. Overall, the func-
tional and metabolic consequences of chronic administration of capsiate remain conflicting
and it cannot be excluded that these discrepancies would be linked to a dose-dependent effect.
The aim of this study was to further investigate the potential dose-dependent functional,
anatomical and metabolic consequences of chronic capsiate administration, on the basis of in
vivo and in vitro experiments in mice. We have especially tested whether capsiate intake affects
bioenergetics in exercising gastrocnemius muscle. For this purpose, animals were administrat-
ed daily during two weeks with either vehicle (control) or purified capsiate at low (10 mg/kg
body wt) or high (100 mg/kg) concentration. Metabolic fluxes were assessed strictly non-
invasively with respect to mechanical performance using MR imaging and 31P-MRS and oxy-
gen consumption was evaluated in isolated saponin-permeabilized fibers. The corresponding
results were analyzed together with quantification of abdominal fat content using whole-body
MR imaging and changes in UCP3 gene expression.
Materials and Methods
Animal care and feeding
Forty-one C57BL/6 3-month old male mice (Charles River Laboratory, L'Arbresle, France)
were used for these experiments. All animal work and care were performed under the
Effect of Capsiate Supplementation on Muscle Function and Metabolism
PLOSONE | DOI:10.1371/journal.pone.0128016 June 1, 2015 2 / 17
analysis, interpretation and decision to publish the
present study.
supervision of BG (with personal license 13.164 2008/11/25 covering the experiments reported
in the manuscript) and conducted in strict accordance with the guidelines of the European
Communities Council Directive 86/609/EEC for Care and Use of Laboratory Animals with the
approval of the animal experiment committee of Aix-Marseille University. Animals were so-
cially housed as 4–6 per cage in an environmentally controlled facility (12-h light cycle, 22°C)
with free access to food and water until the time of the experiment. At the end of experiments,
animals were euthanized by cervical dislocation following isoflurane anesthesia and gastrocne-
mius muscle were removed for in vitro measurements. All reasonable efforts were made to
minimize the number and the suffering of animals.
Experimental design
Capsiate provided by Ajinomoto (Tokyo, Japan) was synthesized as reported previously [16].
Capsiate vehicle, i.e., a solution containing 0.9% NaCl, 3% ethanol and 10% Tween 80 [8] was
used as control solution. On a daily basis and during a 2-week period, animals were adminis-
trated control or capsiate (at 10- or 100-mg/kg body weight) solution by stomach intubation
using a round-ended needle. Two testing sessions were performed. In the first session, which
was conducted at the end of the 2-week treatment period, energy metabolism and function
were investigated strictly noninvasively in gastrocnemius muscle using 31P-MR spectroscopy
and MR imaging. For this purpose, 23 animals were randomly assigned to three groups, i.e.,
control (n = 7), capsiate at 10- (n = 8) or 100-mg/kg (n = 8). The second session was conducted
in three additional groups (vehicle, capsiate at 10- or 100-mg/kg; 6 animals per group). Ab-
dominal fat was quantified using in vivo MR imaging before and at the end of the 2-week peri-
od. Animals were then euthanized and both gastrocnemius muscles were removed, dissected
free of collagen tissue and surrounding fat. The first gastrocnemius muscle was immediately
freeze-clamped with liquid nitrogen-chilled metal tongs for measuring UCP3 gene expression
and ATP content. The second muscle was placed in an ice-cold isolation solution (Krebs solu-
tion containing 2.77 mM of CaK2EGTA, 7.23 mM of K2EGTA, 6.56 mM of gCl2, 5.70 mM of
Na2ATP, 15 mM of PCr, 20 mM of imidazole, 20 mM of taurine, 0.50 mM of dithiothreitol, 50
mM of K-methansulfonate; pH 7.1 at 22°C) for analyzing mitochondrial function on permeabi-
lized muscle fibers.
Noninvasive investigation of gastrocnemius muscle function and
energetics
Animal preparation. Animals were initially anesthetized in an induction chamber using
1.75% isoflurane in 33% O2 (0.2 L/min) and 66% N2O (0.4 L/min). The left hindlimb was
shaved and electromyography cream was applied at the knee and heel regions for optimizing
transcutaneous electrostimulation of gastrocnemius muscle. Muscle contractions were elicited
using transcutaneous surface electrodes connected to an electrical stimulator (Type 215/T;
Hugo Sachs Elektronik-Harvard Apparatus GmbH, March-Hugstetten, Germany). Ophthal-
mic cream was applied to protect corneas from drying. Each anesthetized mouse was placed su-
pine into a home-built experimental device allowing the strictly noninvasive MR investigation
of gastrocnemius muscle energy metabolism and function [17]. During experiment, anesthesia
was maintained with a home-built facemask continuously supplied with 1.75% isoflurane in
33% O2 (0.2 L/min) and 66% N2O (0.4 L/min). The lower hindlimb was positioned inside a 20
mm-diameter Helmholtz-type imaging coil so that the belly of the gastrocnemius muscle was
located above an elliptical (8 x 12 mm) 31P-MR spectroscopy surface coil and the foot was
placed on the pedal of an ergometer including a force transducer. Pedal position was adjusted
for modifying the angle between the foot and the lower hindlimb so that the gastrocnemius
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muscle was passively stretched at rest in order to produce a maximum isometric twitch tension
in response to supramaximal square wave pulses (1.5 ms duration; 15–20 mA). Body tempera-
ture was controlled and maintained at a physiological level throughout the experiment using a
feedback loop including an electrical heating blanket, a temperature control unit (ref. 507137;
Harvard Apparatus, Holliston, MA, USA) and a rectal thermocouple probe.
Mechanical performance measurements. The analog electrical signal coming out from
the force transducer was amplified (AD620 operational amplifier; Analog Devices, Norwood,
MA, USA; 70 dB gain; 0–5 kHz bandwidth) and converted to a digital signal (PCI-6220; Na-
tional Instrument, Austin, TX, USA) that was continuously monitored and recorded on a per-
sonal computer using the WinATS 6.5 software (Sysma, Aix-en-Provence, France). Isometric
force production (expressed as force-time integral) was calculated every 15 sec by integrating
the absolute isometric tension (in N) with respect to time, and was normalized with gastrocne-
mius muscle volume calculated from hindlimb MR images (see below).
MR data acquisition. MR investigations were done in the 4.7-Tesla horizontal magnet of
a 47/30 Biospec Avance MR system (Bruker, Karlsruhe, Germany) equipped with a Bruker
120-mm BGA12SL (200 mT/m) gradient insert. Ten noncontiguous axial imaging slices
(1-mm thickness, 0.5-mm spaced) were acquired across the resting lower hindlimb using a
RARE sequence (8 echoes; 67.9-ms effective echo time; 16.7-ms actual echo time; 2000-ms rep-
etition time; one accumulation; 20 x 15 mm2 field of view; 256 x 256 matrix size). 31P-MR spec-
tra (8-kHz sweep width; 2048 data points) from the gastrocnemius region were continuously
acquired throughout a standardized rest-exercise-recovery protocol consisting of 6 min of rest,
6 min of repeated maximal isometric contractions electrically induced at a frequency of 1.7 Hz,
and 15 min of post-electrostimulation recovery. A fully relaxed spectrum (12 scans, 20-s repeti-
tion time) was recorded at rest, and was followed by 768 saturated free induction decays (FID;
1.875-s repetition time). The first 64 FIDs were acquired at rest and summed together. The
next 192 FIDs were obtained during the electrostimulation protocol and were summed by
packets of 32, thereby allowing a 60-s temporal resolution. The remaining 512 FIDs were ac-
quired during the recovery. The first 224 FIDS were summed as 7 packets of 32; the following
192 FIDs were summed by packets of 64 and the last 96 FIDs were summed together.
MR data processing. Imaging and spectroscopy MR data were processed using custom-
written analysis programs developed using IDL software (Interactive Data Language, Research
System, Inc., Boulder, CO, USA) [18, 19]. For each MR image, region of interest was manually
outlined so that the corresponding cross sectional area of the gastrocnemius muscle was mea-
sured. Muscle volume was calculated as the sum of the six volumes included between seven
consecutive slices. Relative concentrations of phosphorylated compounds were obtained from
31P-MR spectra with a 60-s time resolution by a time-domain fitting routine using the AMAR-
ES-MRUI Fortran code and appropriate prior knowledge for the ATP multiplets [20]. Absolute
concentrations were expressed relative to a resting -ATP concentration measured in vitro
using high-performance liquid chromatography (see below). Intracellular pH (pHi) was calcu-
lated from the chemical shift of the Pi peak relative to that of PCr [21].
Metabolic fluxes calculation. ATP production rates from oxidative and anaerobic path-
ways were calculated in contracting gastrocnemius muscle according to the quantitative inter-
pretation of bioenergetics data [22–24].
Oxidative ATP production rate (Q) was calculated considering that ADP stimulates mito-
chondrial ATP synthesis through a hyperbolic function [25]: Q = Qmax/(1+Km/[ADP]), where
Qmax is the maximal oxidative ATP synthesis capacity and Km is the ADP concentration at
half-maximal rate of oxidative ATP synthesis. Km was determined for each group from oxygen
consumption measurement in permeabilized fibers (see below). ADP concentration was calcu-
lated from [PCr], [ATP] and pHi considering the equilibrium constant (K = 1.67 10
9 M-1) of
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the creatine kinase (CK) reaction [26]. Qmax was calculated using the initial rate of PCr resyn-
thesis at the start of the recovery period (VPCrrec) and ADP level at the end of the electrostimu-
lation protocol: Qmax = VPCrrec (1+Km/[ADP]end). VPCrrec was the product of krec (the
pseudo-first-order rate-constant of PCr recovery) and ΔPCr (the amount of PCr consumption
measured at the end of the electrostimulation protocol). In order to determine krec, the time-
course of post-electrostimulation PCr resynthesis was fitted to a first-order exponential curve
with a least mean-squared algorithm: krec = -[ln(PCrt/ΔPCr]/t.
Anaerobic ATP production was calculated as the sum between ATP produced by PCr deg-
radation via CK reaction and by glycolysis. The rate of ATP production from the CK reaction
(D) was directly calculated using the [PCr] time-course throughout the electrostimulation pro-
tocol: D = -dPCr/dt. Glycolytic ATP production rate (L) was inferred at any time point of the
electrostimulation protocol considering that L is related to glycolytic proton generation (HGly)
with a stoichiometry of 1.5 moles ATP per mole of proton: L = 1.5HGly [27].HGly was calculat-
ed from the changes in pHi after correcting by protons (i) consumed by PCr degradation via
CK reaction (HCK), (ii) passively buffered in the cytosol (Hβ), (iii) leaving the cell (HEfflux) and
(iv) produced by oxidative phosphorylation (HOx):HGly =HCK+Hβ+HEfflux-HOx. Calculation
ofHCK was done from the stoichiometric coefficient (φ = 1/(1+10
(pHi-6.75)) representing the
number of protons generated per mole of PCr degraded [28]: HCK = φdPCr/dt. Proton buffer-
ing was the product of the apparent gastrocnemius buffering capacity (βtotal, in Slykes, milli-
moles acid added per unit change in pHi) and pHi changes (ΔpHi = pHobserved-pHrest):Hβ =
-βtotalΔpHi, in which βtotal takes into account the buffering capacity of Pi (βPi = 2.3[Pi]/((1+-
10(pHi-6.75))(1+10(6.75-pHi)) [28]) and the tissue buffering capacity (βtissue), which varies linearly
between pH 7 (16 Slykes) and pH 6 (37 Slykes) in murine gastrocnemius muscle [29]. During
the electrostimulation protocol, Hefflux was calculated from the linear proportionality constant
λ (in mM/min/pH unit) relating proton efflux rate and pHi:Hefflux = -λΔpHi. This constant
was determined at the start of the recovery period (λ = -Hefflux/ΔpHi) considering that, despite
the intracellular proton load associated with aerobic PCr resynthesis, pHi recovers back to its
basal value as a result of a net proton efflux from the cell. Hence, Hefflux can be calculated con-
sidering proton production from CK reaction and mitochondrial ATP synthesis and pH
changes: Hefflux =HCK +HOx +βtotaldpHi/dt. Proton production by oxidative ATP synthesis
was quantified from the coefficientm representing the number of proton produced by mole of
ATP generated through oxidative phosphorylation [28]:HOx =mVPCrrec, withm = 0.16/(1
+10(6.1-pH)).
Energy cost of contraction. PCr cost of contraction was calculated by scaling the initial
rate of PCr degradation (VPCrstim) at the onset of the electrostimulation protocol to the
amount of force produced during the first 15-s interval of the protocol. VPCrstim was calculated
as the product of kstim (the pseudo-first-order rate-constant of PCr degradation) and [PCr]cons
(the amount of PCr consumed at the end of the electrostimulation protocol). The constant
kstim was determined by fitting the time-course of PCr degradation to a single exponential
curve described by the equation: [PCr]t = [PCr]end+[PCr]conse
-kt, where [PCr]end is the concen-
tration of PCr measured at the end of the electrostimulation protocol. Oxidative and glycolytic
costs of contraction were calculated at the onset and at the end of the electrostimulation proto-
col as the ratio between raw ATP production and force output during the same period of time
In vivo quantification of abdominal fat depot
Animals were anesthetized as described above, and axial MR images of the abdominal region
were acquired using a proton probe (PRK 200 RES 200, Bruker, Karlsruhe, Germany) and a
high-resolution 3-D (turbo spin echo) sequence with the following parameters: 5.530-ms echo
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time; 77.85-ms effective echo time; 300-ms repetition time; 2 averages; 40 x 40 x 40 mm3 field
of view, 128 x 128 x 64 matrix size. Absolute quantification of abdominal fat depots was pro-
cessed using a custom-written analysis program developed on the IDL software.
UCP3 gene expression
To quantify UCP3 mRNA expression, real-time PCR was performed with a Light Cycler 480
SYBR Green I Master (Roche Applied Science France). Eukaryotic 18S rRNA was used as inter-
nal housekeeping gene. The specific primers were: UCP-3 forward 5’ TAC CCA ACC TTG GCT
AGA CG 3’ and reverse 5’ GTC CGA GGA GAG AGC TTG C 3’; 18S forward 5’ ACC GCG GTT
CTA TTT TGT TG 3’ and reverse 5’ AGT CGG CAT CGT TTA TGG TC 3’. Briefly, total RNA
was extracted from freeze-clamped gastrocnemius muscle (RNeasy Fibrous Tissue Mini kit,
Qiagen France) and RNA quantity was determined by reading 1 μL of RNA with a NanoDrop
ND-1000 spectrophotometer (Thermo Fisher Scientific, France). RNA (1 μg) was reverse tran-
scribed (QuantiTect Reverse Transcription kit, Qiagen France) and the equivalent of 5 ng of
initial RNA was subjected to PCR amplification in a 6 μl final volume with 0.5 μM each of the
forward and reverse primers. The standard amplification program included an initial 10-min
denaturation at 95°C followed by 45 cycles consisting of 10 s at 95°C, 15 s at 60°C and 15 s at
72°C. Melting-curve analysis were done for confirming the generation of specific PCR prod-
ucts. Each sample was run in triplicate with serial dilutions of a cDNA mixture to generate a
standard linear curve that was used to estimate relative mRNA expression of UCP-3 normal-
ized with 18S.
Intramuscular ATP content
Freeze-clamped gastrocnemius muscles (10 to 20 mg) were homogenized in 1.2 mL of ice-cold
0.6 M perchloric acid. After 15-min incubation at 4°C, the homogenates were centrifuged (15
min, 2000 x g, 4°C) and the pellets were dissolved into 1 ml NaOH for protein calculation [30].
After pH neutralization with K2CO3 and 30-min incubation at 4°C, the supernatants were used
for ATP content determination with an ion-pairing reverse-phase high-performance liquid
chromatography (HPLC) system (Merck-Hitachi L-6200A pump and L-7400 UV-visible de-
tector, Darmstadt, Germany) [31]. Thymidine monophosphate (T7004; Sigma, Poole, UK) was
used as an internal standard.
Mitochondrial respiration on permeabilized fibers
Respiratory parameters of the total mitochondrial population were studied in permeabilized
saponin-skinned fibers according to Kuznetsov et al. [32]. Briefly, thin fiber bundles (100–
200 μm in diameter) were excised from muscles in isolation solution, and the fibers were man-
ually separated from each other. Sarcolemma permeabilization was done by incubating dissect-
ed fibers for 30 min with gentle shaking in the same solution containing 50 mM of saponin.
Fibers were then transferred for 10 min into a respiration solution (pH 7.1 at 22°C) containing
2.77 mM of CaK2EGTA, 7.23 mM of K2EGTA, 1.38 mM of MgCl2, 3 mM of K2HPO4, 20 mM
of imidazole, 20 mM of taurine, 0.50 mM of dithiothreitol, 90 mM of K-methansulfonate, 10
mM of Na-methansulfonate, 5 mM of glutamate, 2 mM of malate, 2 mg/ml of fatty acid—free
bovine serum albumin. This step was repeated twice in order to wash out saponin and metabo-
lites that could interfere with measurements. Mitochondrial respiration rate was measured at
22°C with a Clark electrode integrated in a water-jacketed oxygraphic cell (Hansatech Instru-
ments Ltd, Norfolk, England) containing 1–2 mg of fibers in 1.5 mL of respiration solution
with continuous stirring. ADP sensitivity was measured by stepwise addition of ADP (from 5
to 2000 μM). The apparent Km for [ADP] was calculated by plotting the ADP-stimulated
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respiration rate (VADP) to a non-linear fitting of the Michaelis-Menten equation. The maximal
oxidative capacity (Vmax) was calculated as the sum between r0 (the basal respiration rate mea-
sured without ADP addition) and rmax (the maximal respiration rate reached with cumulative
addition of ADP).
Statistics
All values are presented as means ± SEM. Statistical analyses were performed using JMP soft-
ware version 9 (SAS Institute Inc., Cary, NC, USA). Two-way (group × time) analysis of vari-
ance (ANOVAs) with repeated measures on time were used to compare the changes during the
6-min electrostimulation protocol for isometric force production, metabolites levels and pHi.
Other differences were tested using one-way (group) ANOVAs. When a main effect or a signif-
icant interaction was found, Tukey post-hoc multiple comparisons test was used for determin-
ing pairwise time-points differences between groups. For all tests, the level of significance was
set at P< 0.05.
Results
Body weight, food consumption and abdominal fat volume
The effects of 2-week daily administration of vehicle or capsiate on food consumption, body weight
and abdominal fat volume are summarized in Table 1. Over the course of the 2-week period, food
intake did not differ between groups, but body weight gain and abdominal fat content were both re-
duced in the group receiving the higher dose of capsiate when compared with control animals.
Muscle volume and mechanical performance
Gastrocnemius muscle volume (121 ± 5 mm3, 134 ± 4 mm3 and 139 ± 2 mm3 in control,
10-mg and 100-mg capsiate group, respectively) measured fromMR images after the 2-week
treatment was larger (+11% and +16% in 10-mg and 100-mg capsiate group, respectively) in
animals receiving capsiate when compared to control group (Fig 1A). The overall time-course
of muscle force during the 6-min electrostimulation protocol (Fig 1B), the extent of force re-
duction (expressed as percent of onset electrostimulation-protocol value) measured at the end
of the protocol (Fig 1C) and the total force developed during the whole protocol (Fig 1D) were
not affected by any of both capsiate treatments.
Metabolic changes
In resting muscle, there were no differences among the groups for [PCr]/[ATP] ratio, [ATP]
and [ADP] (Table 2). On the contrary, [PCr] was lower (-15%) in the group receiving the
higher dose of capsiate compared to control animals, and basal pHi was larger in both groups
Table 1. Food intake, body weight and abdominal fat gain over 2-week daily administration of vehicle or capsiate.
Control Capsiate 10 mg/kg Capsiate 100 mg/kg
Body weight before treatment (g) 25.3 ± 0.4 25.4 ± 0.4 25.6 ± 0.5
Body weight gain (g) 0.92 ± 0.65 0.32 ± 0.36 -0.41 ± 0.16*
Food intake (g/animal) 39.9 ± 1.5 41.5 ± 2.3 41.2 ± 2.1
Abdominal fat gain (cm3) 1.06 ± 0.38 -0.39 ± 0.46 -0.68 ± 0.51*
Values are means ± SEM. n = 6 per group.
*Signiﬁcantly different from control in the same row.
doi:10.1371/journal.pone.0128016.t001
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receiving capsiate (Table 2). At the onset of the electrostimulation protocol, PCr was rapidly
degraded (Fig 2A) at a similar rate among the groups (Table 2). After 2–3 min of electrostimu-
lation, [PCr] reached a steady state that remained stable until the end of the protocol (Fig 2A).
At that time, the extent of PCr degradation did not differ among the groups (Table 2). It is
noteworthy that the initial difference regarding the resting PCr level between control and
100-mg capsiate groups was kept approximately constant during the whole electrostimulation
Fig 1. Muscle anatomy andmechanical performance in vivo.Gastrocnemius muscle volume (A) and force produced throughout the 6-min fatiguing
electrostimulation protocol performed at the end of 2-week treatment with vehicle (control) or capsiate (CAP) at 10- or 100-mg/kg body weight (B). Extent of
force reduction measured at the end of the protocol and expressed as percent of onset value (C). Total amount of force produced during the whole 6-min
electrostimulation (D). Data are means ± SEM. * Significantly different (one-way ANOVA; P < 0.05) from control.
doi:10.1371/journal.pone.0128016.g001
Table 2. Effect of 2-week daily administration of vehicle or capsiate onmouse gastrocnemius bioenergetics assessed in vivo using 31P-MR
spectroscopy.
Control Capsiate 10 mg/kg Capsiate 100 mg/kg
n = 7 n = 8 n = 8
Resting period
[PCr]/[ATP] ratio 2.75 ± 0.12 2.74 ± 0.07 2.63 ± 0.11
[PCr] (mM) 16.4 ± 0.7 15.2 ± 0.4 14.1 ± 0.6*
[ATP] (mM) 5.9 ± 0.3 5.5 ± 0.2 5.3 ± 0.2
[ADP] (μM) 9 ± 1 11 ± 1 10 ± 1
pHi 7.13 ± 0.02 7.26 ± 0.03* 7.23 ± 0.02*
Onset of the electrostimulation protocol
Initial rate of PCr degradation (mM/min) 11.5 ± 1.5 9.6 ± 1.0 10.0 ± 1.0
[ATP] (mM) 5.9 ± 0.4 5.3 ± 0.2 5.3 ± 0.3
[ADP] (μM) 20 ± 4 26 ± 2 27 ± 1
End of the electrostimulation protocol
ΔPCr (relative to basal; %) 66 ± 3 69 ± 2 72 ± 2
[ATP] (mM) 5.9 ± 0.5 5.2 ± 0.6 5.1 ± 0.5
[ADP] (μM) 47 ± 7 57 ± 9 60 ± 4
ΔpHi (relative to basal; pH unit) 0.42 ± 0.04 0.44 ± 0.03 0.42 ± 0.03
Post-electrostimulation recovery period
Initial rate of PCr resynthesis (mM/min) 4.9 ± 0.4 4.4 ± 0.6 3.5 ± 0.4
Values are means ± SEM.
*Signiﬁcantly different from control in the same row.
doi:10.1371/journal.pone.0128016.t002
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protocol (Fig 2A). The time-course of pHi during repeated muscle contractions was strongly
similar among the groups, with a rapid acidosis in the early phase of the protocol, followed by a
phase of fairly steady state (Fig 2B). Interestingly, muscle acidosis during the protocol was sig-
nificantly lower in both groups receiving capsiate (Fig 2B). For each group, ATP level remained
close to the basal value during the whole electrostimulation protocol (Fig 2C), whereas ADP
level continuously increased (Fig 2D) to reach an end-exercise value that did not differ between
groups (Table 2). During the recovery period, PCr, ATP, ADP and pHi progressively reached
towards their respective basal value. Importantly, the initial rate of PCr resynthesis was not al-
tered in both groups receiving capsiate (Table 2).
Metabolic fluxes and energy cost of contraction
Capsiate treatment did not change the overall time-course of oxidative and anaerobic ATP pro-
duction rates throughout the electrostimulation period (Fig 3A and 3B). However, oxidative
Fig 2. Phosphorylated compounds and pH in mouse gastrocnemius muscle in vivo.Changes in gastrocnemius muscle [PCr] (A), intracellular pH (B),
[ATP] (C) and [ADP] (D) throughout the 6-min fatiguing electrostimulation protocol performed at the end of 2-week treatment with vehicle (control) or capsiate
(CAP) at 10- or 100-mg/kg body weight. The first time point (t = 0) indicates the resting value. Data are means ± SEM. P-value indicates the overall result of
the two-way repeated measures ANOVA. When justified (P-value < 0.05), Tukey post-hoc multiple comparison was used for determining pairwise differences
between groups: # Significant difference between CAP 10-mg and control. $ Significant difference between CAP 100-mg and control.
doi:10.1371/journal.pone.0128016.g002
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ATP production rate was increased for each group between the onset and the end of the elec-
trostimulation protocol, but this increase was lower in both groups receiving capsiate (-44%
and -48%, in 10- and 100-mg groups, respectively) (Fig 3A). Besides, the relative contribution
of oxidative ATP production to total ATP production did not differ between groups, averaging
~10% and ~67% at the onset and at the end of the electrostimulation protocol, respectively
(Fig 4). There were no differences among the groups for PCr cost (Fig 5A) and oxidative (Fig
5B), glycolytic (Fig 5C) and total (Fig 5D) ATP cost of contraction at the onset of the electrosti-
mulation protocol. At the end of the protocol, oxidative cost of contraction was significantly
lower in both groups receiving capsiate (-33% and -44% in the 10-mg and 100-mg group, re-
spectively) (Fig 5B), and total ATP cost was significantly lower (-25%) in the 100-mg group
when compared to control (Fig 5D).
Mitochondrial respiration on permeabilized fibers
Both capsiate treatments did alter neither the basal respiration rate nor the maximal oxidative
capacity, but reduced the Km of mitochondrial respiration for ADP in the 10-mg (- 56%) and
the 100-mg (-64%) capsiate-treated animals when compared to the control group (Table 3).
UCP3 gene expression
UCP3 mRNA levels in gastrocnemius muscle measured after the 2-week treatment period did
not differ among the groups (Fig 6).
Discussion
The aim of this study was to examine the functional, anatomical and metabolic consequences
of chronic administration of a low (10 mg/kg body wt) and a high (100 mg/kg) dose of purified
capsiate on mice gastrocnemius muscle. The major findings are that, regardless of the dose,
capsiate treatment: (i) did affect neither UCP3 gene expression nor both basal and maximal ox-
ygen consumption in permeabilized muscle fibers, but decreased by about twofold the Km of
mitochondrial respiration for ADP; (ii) promoted gastrocnemius muscle mass gain;
Fig 3. Oxidative and anaerobic ATP productions in contracting mouse gastrocnemius muscle in vivo. Effect of 2-week treatment with vehicle (control)
or capsiate (CAP) at two different concentrations (10- or 100-mg/kg body weight) on the time-course of oxidative (A) and anaerobic (B) ATP production rates
calculated from in vivo 31P-MR spectroscopy data throughout the 6-min fatiguing electrostimulation protocol. Data are means ± SEM. * Significantly different
(one-way ANOVA; P < 0.05) from control.
doi:10.1371/journal.pone.0128016.g003
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(iii) markedly disturbed basal bioenergetics in vivo; (iv) reduced oxidative cost of contraction;
(v) did not affect force-generating capacity nor fatigability. In addition, treatment with the
higher dose also reduced body weight gain and abdominal fat content.
Our data show that 2-week daily administration of the higher dose of capsiate reduced body
weight gain and abdominal fat content as measured fromMR images, which is consistent with
previous experiments in human [3] and rodent models [4, 5, 9]. Moreover, we found that these
changes were not associated to any reduction of food intake, hence indicating that mice treated
with capsiate did ingest the same amount of calories as control animals. Our findings add then
further evidence that capsiate suppresses body fat accumulation likely as a result of an in-
creased calories burning.
On the basis of respiratory gas analysis reporting that capsiate supplementation increases
resting oxygen consumption, it has been proposed that the anti-obesity effect of capsiate was
due to an acceleration of basal fat oxidation [3, 8]. Nevertheless, these measurements were
done at the whole-body level and did not provide information related to the specific tissue acti-
vated by capsiate although adipose tissue and skeletal muscle have been considered as the most
likely candidates [9]. In the present study, permeabilized fibers experiments shown that both
capsiate treatments did alter neither the basal nor the maximal respiration rate, which suggests
that capsiate does not increase fat oxidation capacity in skeletal muscle. However, it must be
point that increased fat oxidation in skeletal muscle has already been observed without any
concomitant acceleration of mitochondrial respiration in the case that UCP3 expression in-
creases [33, 34], UCP3 playing a major role in skeletal muscle energy expenditure through the
uncoupling of mitochondrial oxygen consumption by the respiratory chain from ATP synthe-
sis [14]. Yet, a single dose of capsiate at 10 mg/kg body weight has been shown to increase
UCP3 gene expression by 100% within two hours in mice [9]. Nevertheless, we found that the
2-week capsiate treatments at low or high dose did not affect UCP3 expression thereby ruling
Fig 4. Metabolic fluxes contributions in contracting muscle.Relative contributions of oxidative and anaerobic pathways to total ATP production at the
onset and at the end of the 6-min fatiguing electrostimulation protocol performed after 2-week treatment with vehicle (control) or capsiate (CAP) at two
different concentrations (10- or 100-mg/kg body weight). Data are means ± SEM.
doi:10.1371/journal.pone.0128016.g004
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out the hypothesis of an increased uncoupling leading to an acceleration of fat oxidation with-
out changes in mitochondrial respiration. Overall, these findings exclude skeletal muscle as a
potential candidate mediating the anti-obesity effect of capsiate.
Capsiate treatments caused however marked alterations in muscle bioenergetics in vivo. At
rest, both treatments increased intracellular pH (i.e., decreased H+ concentration), whereas
ATP and ADP contents remained unaffected, and the higher dose of capsiate also reduced
Fig 5. Energy cost of muscle contraction. Effect of 2-week treatment with vehicle (control) or capsiate (CAP) at two different concentrations (10- or
100-mg/kg body weight) on PCr cost (A) and oxidative (B), glycolytic (C) and total (D) ATP cost of contraction at the onset and at the end of the 6-min
fatiguing electrostimulation protocol. Data are means ± SEM. * Significantly different from control.
doi:10.1371/journal.pone.0128016.g005
Table 3. Effect of 2-week daily administration of vehicle or capsiate on respiration parameters in isolated permeabilized fibers from gastrocnemius
muscle.
Control Capsiate 10 mg/kg Capsiate 100 mg/kg
Basal rate of O2 consumption (μmol/min/g) 1.52 ± 0.09 1.82 ± 0.14 1.46 ± 0.16
Maximal rate of O2 consumption (μmol/min/g) 3.03 ± 0.29 3.17 ± 0.49 3.01 ± 0.20
Km for ADP (μmol/L) 159 ± 29 69 ± 20* 56 ± 10*
Values are means ± SEM. n = 6 per group.
*Signiﬁcantly different from control in the same row.
doi:10.1371/journal.pone.0128016.t003
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basal PCr content. During the whole 6-min fatiguing electrostimulation protocol, these initial
differences between control and capsiate group regarding basal pH and PCr content were kept
approximately constant, although capsiate treatments did not alter the time-changes in ATP
and ADP levels. Intramuscular PCr level is controlled by the CK reaction, which transfers
high-energy phosphate from PCr to ADP to form ATP (PCr + ADP + H+$ ATP + creatine)
[35] and CK/PCr system is considered to play a crucial role in muscle bioenergetics during ex-
ercise [36, 37]. A large part of CK activity is ensured by cytosolic CK, which is mainly localized
at the fibrillar M-line in association with sarcoplasmic reticulum Ca2+ pumps [37]. The re-
maining activity is due to mitochondrial CK situated in the intermembrane space of mitochon-
dria. The PCr-CK system functions at once as an energy buffer and as an energy carrier in
order to maintain ATP homeostasis in exercising muscle [38, 39]. The first function, which is
mainly effective at the transition from rest to exercise, allows maintaining ATP pool unchanged
despite energy demand might be increased by more than 100-fold. The second function is di-
rectly involved in the transport of high-energy phosphate between the site of production (mito-
chondria) and utilization (myofilaments cross-bridges and ion pumps) of ATP. In the present
study, it is therefore surprising that both PCr and H+ contents were reduced whereas ADP and
ATP levels were not affected because considering the CK reaction equilibrium, any reduction
in both PCr and H+ contents should result in an increased ADP level in order to maintain ATP
homeostasis. At the first glance, these findings suggest that capsiate disturbs the PCr-CK sys-
tem function. However, it is unlikely that the apparent energy buffer function of PCr-CK sys-
tem was affected since we found that PCr cost of contraction and ATP level at the onset of the
electrostimulation period were not altered by capsiate treatment, thereby indicating that the
Fig 6. UCP3 gene expression. Basal UCP3 mRNA levels in gastrocnemius muscle normalized to 18S
mRNA used as an internal standard in animals daily administered during two weeks with vehicle (control) or
capsiate (CAP) at two different concentrations (10- or 100-mg/kg body weight). Data are means ± SEM.
doi:10.1371/journal.pone.0128016.g006
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rate of PCr degradation entirely fits ATP demand for contraction. Furthermore, we found that
both capsiate treatments did not affect the rate of PCr resynthesis, an in vivo index of the end-
exercise rate of oxidative ATP synthesis [23, 40], hence suggesting that the energy transport
function of PCr-CK system was not altered. Interestingly, we found in permeabilized fibers
that both capsiate treatments decreased the Km of mitochondrial respiration for ADP, which
indicates an improvement of mitochondrial sensitivity for ADP [41, 42]. Given that ADP stim-
ulates mitochondrial ATP synthesis through a feedback loop [23, 25], the higher mitochondrial
sensitivity for ADP combined with unchanged ADP level should lead to an acceleration of the
mitochondrial ATP synthesis. The absence of such an issue herein suggests that capsiate alters
the feedback loop of ADP on oxidative metabolism.
Another important finding is that both capsiate treatments led to a reduction in oxidative
cost of contraction in the latter phase of the fatiguing protocol, hence indicating that less oxida-
tive ATP was needed for a given amount of force. Capsiate is known to increase Ca2+ release
from the sarcoplasmic reticulum via the activation of TRPV1 receptors in skeletal muscle [11,
43]. Thus, the reduced cost of contraction could be linked to an enhanced response of contrac-
tile elements to Ca2+ in combination with an improvement of the kinetics of attachment and
detachment of cross-bridges with repeated muscle contractions, as already proposed in exercis-
ing muscle of mice receiving a single dose of capsiate [44]. Moreover, it must be underlined
that both capsiate treatments did affect neither glycolytic cost of contraction nor the balance
between oxidative and anaerobic ATP production, indicating that the improvement of oxida-
tive function did not occur at the expense of other metabolic pathways.
We found also that gastrocnemius muscle volume was larger in groups treated with capsiate
at low (+11%) and high (+16%) doses when compared to control animals. This result corrobo-
rates those from a previous study showing that 2-week daily administration of capsiate at 10
mg/kg increases gastrocnemius muscle weight by 16% [9], and supports the hypothesis that
capsiate promotes muscle growth. One can assume that this hypertrophic effect is mediated by
the capsiate-induced activation of TRPV1 receptors, resulting in an increased cytosolic Ca2+
level that subsequently triggers the mammalian target of rapamycin (mTOR) [45]. Upregula-
tion of the mTOR signaling pathway actually causes muscle hypertrophy via an increased pro-
tein synthesis [46, 47]. Our assumption is supported by previous experiments showing that
chronic administration of capsiate at 10 mg/kg during 4 weeks increases protein intake in hu-
mans [12]. In addition, it is tempting to speculate that capsiate-induced muscle hypertrophy
contributes to the anti-obesity effect of this compound, given that hypertrophied muscle favors
fat utilization for growth and maintenance [48]. On the other hand, it is noteworthy that capsi-
ate-induced muscle hypertrophy did affect neither the force-generating capacity nor muscle fa-
tigability, which is consistent with previous works reporting that acute and chronic
administration of capsiate do not affect mechanical performance [4, 49].
Overall, the present work demonstrates that, in addition to its anti-obesity effect, chronic
administration of capsiate promotes muscle mass gain and improves oxidative metabolism
in exercising muscle. These data strengthen capsiate as a natural compound for
improving health.
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